In 1 BPT+RMI patient (patient 2), hypersomnia was improved within 2 weeks and decreased CSF hypocretin-1 levels were reversed (acute phase, 109.2 pg/mL; chronic phase, 323 pg/mL), whereas another BPT+RMI patient (patient 1) who displayed coma in the acute phase had decreased CSF orexin levels (107 pg/mL) at day 49 and exhibited severe functional disability. This evidence concerns the gene HCRT and Coma.